US5880090A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of vascular graft implants with G-CSF
Assignee: Hope Heart Institute
•
Filing: 1997-09-19
•
Granted: 1999-03-09
•
Expires: 2017-09-19
Abstract
Abstract This invention provides methods for enhancing the endothelialization of synthetic vascular grafts by administering to a graft recipient an agent that mobilizes bone marrow-derived CD34+ cells into the bloodstream, that enhances the adherence to graft surfaces of blood-borne endothelial progenitors, or that stimulates the multiplication of endothelial progenitors that have adhered to the graft surfaces.
Inventors
- 👤 William P. Hammond
- 👤 Qun Shi
- 👤 Moses Hong-De Wu
- 👤 Errol S. Wijelath
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 22:14
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/193; A61K35/00; A61K35/12; A61K35/28
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
56 words
A method for promoting endothelialization of a synthetic vascular graft comprising administering to a recipient of the synthetic vascular graft an agent capable of increasing the concentration in the recipient's blood of bone marrow-derived endothelial progenitors, said agent being administered in an amount sufficient to increase the concentration in the graft recipient of said endothelial progenitors.
Claim 2
Independent Claim
56 words
A method for promoting endothelialization of a synthetic vascular graft comprising administering to a recipient of the synthetic vascular graft an agent capable of increasing the concentration in the recipient's blood of bone marrow-derived endothelial progenitors, said agent being administered in an amount sufficient to increase the concentration in the graft recipient of said endothelial progenitors.
Claim 3
Dependent Claim
28 words
The method of claim 1, wherein the agent is selected from the group consisting of stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF).
Claim 4
Dependent Claim
10 words
The method of claim 2, wherein the agent is G-CSF.
Claim 5
Dependent Claim
15 words
The method of claim 1, wherein the synthetic vascular graft is composed of polyethylene terephthalate.
Claim 6
Dependent Claim
21 words
The method of claim 1, wherein the synthetic vascular graft is from about 2 to about 9 mm in internal diameter.
Claim 7
Dependent Claim
21 words
The method of claim 5, wherein the synthetic vascular graft is from about 3 to about 5 millimeters in internal diameter.
Claim 8
Dependent Claim
16 words
The method of claim 1, wherein the agent is administered daily for 1 to 14 days.
Claim 9
Dependent Claim
21 words
The method of claim 1, wherein the agent is administered prior to or within 3-7 days after implantation of the graft.
Claim 10
Dependent Claim
52 words
The method of claim 8, wherein the agent is administered for at least 3 days prior to implantation of the graft, peripheral blood mononuclear cells are collected by apheresis prior to graft implantation, and the collected peripheral blood mononuclear cells are perfused into the graft recipient within 3 days of graft implantation.
Claim 11
Independent Claim
52 words
A method for promoting endothelialization in a synthetic vascular graft wherein the recipient of the synthetic vascular graft is a human comprising administering to the graft recipient an amount of G-CSF sufficient to increase the concentration in the graft recipient of peripheral blood mononuclear cells or cells that express the CD34 antigen.
Claim 12
Independent Claim
52 words
A method for promoting endothelialization in a synthetic vascular graft wherein the recipient of the synthetic vascular graft is a human comprising administering to the graft recipient an amount of G-CSF sufficient to increase the concentration in the graft recipient of peripheral blood mononuclear cells or cells that express the CD34 antigen.
Claim 13
Dependent Claim
15 words
The method of claim 10, wherein the synthetic vascular graft is composed of polyethylene terephthalate.
Claim 14
Dependent Claim
21 words
The method of claim 10, wherein the synthetic vascular graft is from about 2 to about 9 millimeters in internal diameter.
Claim 15
Dependent Claim
21 words
The method of claim 12, wherein the synthetic vascular graft is from about 3 to about 5 millimeters in internal diameter.
Claim 16
Dependent Claim
16 words
The method of claim 10, wherein the G-CSF is administered daily for 1 to 14 days.
Claim 17
Dependent Claim
16 words
The method of claim 10, wherein the G-CSF is administered prior to implantation of the graft.
Claim 18
Dependent Claim
41 words
The method of claim 15, further comprising administering to the graft recipient within 3 days of graft implantation peripheral blood mononuclear cells collected by apheresis from the graft recipient after at least 3 days of G-CSF administration to the graft recipient.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-03-08 | 2002-09-07 | 2003-03-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-03-08 | 2006-09-07 | 2007-03-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-03-08 | 2010-09-07 | 2011-03-09 | $7700.00 | Window Closed / Lapsed |